

Ensayos Clínicos de **TIROIDES** Abiertos a Reclutamiento (Actualizado octubre_2020)

Eudract_Number	NCT	CODIGO_ESTUDIO	TITULO DEL ESTUDIO	FASE_ESTUDIO	INDICACION	ESTADO	MEDICACION	CENTROS_PARTICIPANTES	PROMOTOR	ESPECIALIDAD	COMENTS
2018-002612-27	37809517	BOS172738-01	A Phase 1 Study of BOS172738 in Patients With Advanced Solid Tumors With RET Gene Alterations Including Non-Small Cell Lung Cancer (NSCLC) and Medullary Thyroid Cancer (MTC)	Phase I	Advanced Nonhaematologic Malignancies	RECLUTANDO	BOS172738	H.U.Victoria (Malaga) ICD Badalona (BCN) H.U.Girona (Girona/BCN) START_Sanchinarro(Madrid) START_F.J.Diaz (Madrid)	Boston Pharmaceuticals	Oncologia_Medica	N= 114
2018-004334-15	4224113	SC103	A Multicenter Open-label Phase 1/1b Study to Evaluate the Safety and Preliminary Efficacy of SO-C101 as Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced/Metastatic Solid Tumors	Phase I	HN5CC & Thyroid. A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of SO-C101 as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors	RECLUTANDO	SO-C101 Pembrolizumab	H.U.Val d'Hebron(BCN)	SOTIO	Oncologia_medica	N= 96
2017-001792-24	3172960	XL184-021	A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors	Phase 1b	Expansion Cohort 1B: DTC subjects (follicular, papillary, and poorly differentiated histologies) who are radioactive iodine (RAI) refractory or deemed ineligible for treatment with RAI.	RECLUTANDO	Atezolizumab & Cabozantinib	H.U.Val d'Hebron(BCN) C.M.Teknon (BCN) H.U.Clinic (BCN) H.U. Abr (BCN) C.H.U.Santiago H.U.Son Espases(BJ) H.U.12 Octubre (Madrid)	Exelixis	Oncologia_medica	N= 1732
2016-004190-41	3037385	BLU-667-1101 (ARROW)	A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors	Phase I/II	RET-altered NSCLC Medullary Thyroid Cancer RET-altered Papillary Thyroid Cancer RET-altered Colon Cancer RET-altered Solid Tumors	RECLUTANDO	BLU-667	H.U.Val d'Hebron (BCN) H.U.CINIC(BCN) ICD-Hospitaliet (BCN) H.U.Ramon y Cajal (Madrid) H.U.12 Octubre (Madrid)	Blueprint Medicines Corporation	Oncologia_Medica	N= 360
2017-000800-59	3157138	LOXO-RET-17001	A Phase 1/2 Study of Oral LOXO-292 in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)	Phase I / II	This is a Phase 1/2, open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to patients with advanced solid tumors, including RET-fusion positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.	RECLUTANDO	LOXO-292	H.U.Val d'Hebron (BCN) START_F.J.Diaz (Madrid) START_Sanchinarro (Madrid)	Loxo Oncology, Inc	Oncologia_Medica	N= 970
2016-002143-42	2980817	GCT1021-01	First-in-human, Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (Enapotamab Vedotin, HuMax-Axl-ADC) in Patients With Solid Tumors	Phase I / II	The purpose of the trial is to determine the maximum tolerated dose and to establish the safety profile of HuMax-Axl-ADC in a mixed population of patients with specified solid tumors. Thyroid Cancer	RECLUTANDO	Biological: Enapotamab vedotin (HuMax-Axl-ADC)	H.C.Lozano Blesa(Zaragoza) H.U.Victoria (Malaga) H.U.Puerta Hierro (Madrid) H.U.12 Octubre(Madrid) ICD Girona ICD-Hospitaliet(BCN) H.U.Val d'Hebron (BCN)	Genmab	Oncologia_medica	N= 374
2015-002067-41	2628067	3475-158	A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)	Phase II	Thyroid Carcinoma Salivary Gland Carcinoma (sarcomas and mesenchymal tumors are excluded)	RECLUTANDO	Pembrolizumab	H.U.Val d'Hebron(BCN) H.U.Ramon y Cajal (Madrid) H.U.12 Octubre (Madrid)	Merck Sharp & Dohme Corp	Oncologia_Medica	N= 1350
2015-003385-84	2568267	RXDX-101-02	An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements	Phase II	Head and Neck Neoplasms, Papillary Thyroid Cancer, Salivary Gland Cancers,Adult Solid Tumor	RECLUTANDO	Entrectinib	H.U.Val d'Hebron (BCN) H.U.Ramon y Cajal (Madrid) H.U.Clinico San Carlos(Madrid) H.U.12 Octubre (Madrid) START- CIDCC (Madrid) H.U.Victoria (Malaga) H.U.V.Rocio (Sevilla)	Hoffmann-La Roche / Ignyta, Inc	Oncologia_Medica	N= 300
2018-001066-42	3753919	GETNE-T1812	Estudio de fase II de durvalumab (MED4736) más tremelimumab para el tratamiento de pacientes con carcinoma tiroideo avanzado, resistente al tratamiento y progresivo (ensayo DUTH)	Phase II	Carcinoma de tiroides diferenciado, avanzado, refractario al yodo radiactivo, incluyendo carcinoma tiroideo papilar, folicular, de células de hirsutie y poco diferenciado (CDT), Carcinoma medular de tiroides (CMT) avanzado, Cáncer anaplásico de tiroides (CAT) avanzado.	RECLUTANDO	Durvalumab (L.V)	C.U. Navarra H.U.Val d'Hebron ICD_Hospitaliet BCN H.U.Mariales Menagari (Murcia) H.U.Ramon y Cajal (Madrid) H.U.12 Octubre (Madrid) H.U.La Paz (Madrid) H.U.Victoria (Malaga), H.U.Clinic (BCN) M.D.Anderson(Madrid) H.U.San Chinarro (Madrid) H.U.San Carlos(Madrid) C.H.Castellon I.VO_Valencia H.U.Alvaro Cunqueiro (Vigo)	Spanish Group of Neuroendocrine Tumors (GETNE)	Oncologia_Medica	N= 46
2016-003616-13	3093116	TPX-0005-01	A Phase 1/2, Open-label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)	Phase II in Spain	A Study of Reprectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)	RECLUTANDO	Oral Reprectinib (TPX-0005)	C.U. Navarra H.U.Dones (BCN) H.U.Val d'Hebron(BCN) M.D.Anderson(Madrid) Start_Sanchinarro(Madrid) Start_Sanchinarro(Madrid) H.U.12 Octubre (Madrid) I.V.O.(Barcelona)	Turning Point Therapeutics, Inc.	Oncologia_medica	N= 450
2018-001771-21	3690988	XL184-311	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects With Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-Targeted Therapy	Phase III	The objective of this study is to evaluate the effect of cabozantinib compared with placebo on progression free survival (PFS) and objective response rate (ORR) in subjects with Radioiodine-Refractory Differentiated Thyroid Cancer (DTC) who have progressed after prior VEGFR-Targeted therapy.	RECLUTANDO	Cabozantinib	H.U.12 Octubre(Madrid) H.U.San Carlos (Madrid) H.U.Ramon y Cajal (Madrid) H.U.La Paz (Madrid) H.U.San Chinarro (Madrid) M.D.Anderson (Madrid) C.U.Navarra H.U.Val d'Hebron (Madrid) H.U.Victoria (Malaga) H.U.Clinic (BCN)	Exelixis	Oncologia_medica	N= 300
2019-001978-28	4211337	J2G-MC-IJ2B	A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)	Phase III	The reason for this study is to see if the study drug selpercatinib is safe and more effective compared to a standard treatment in participants with rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) that cannot be removed by surgery or has spread to other parts of the body.	RECLUTANDO	Drug: Selpercatinib Drug: Cabozantinib Drug: Vandetanib	H.V.Victoria(Malaga) H.Clinico (Madrid) H.U.12 Octubre (Madrid) H.U.La Paz (Madrid) H.U.Ramon y Cajal (Madrid) H.U.G.Marñon(Madrid) ICD_Girona ICD_Hospitaliet H.U.Val d'Hebron (BCN) C.U.Navarra H.U.Miguel Servet	Lilly	Oncologia_medica	N= 400
2013-003402-40	1896479	XL184-401	Estudio aleatorizado y doble ciego para evaluar la eficacia y la seguridad de cabozantinib (XL184) con dosis de 60 mg/día en comparación con 340 mg/día en pacientes con cáncer medular de tiroides metastásico progresivo	Phase IV	CMT metastásico progresivo	No Reclutando	Cabozantinib (Oral)	H.U.La Paz, H.U.Val d'Hebron, H.Ramon y Cajal.	Exelixis, Inc	Oncología (La Paz: Endocrino)	N=188
UK	3765333	REGETNE-Tiroides	Descriptive Observational Epidemiological Study on the Characteristics of Thyroid Cancer in Patients Treated in Oncology Services of Spanish Centers: National Registry of Thyroid Cancer - Differentiated, Medullary and Anaplastic	Descriptive Observational	NA	RECLUTANDO	NA	H.U.Val d'Hebron	GETNE	Oncologia_Medica	N= 20
UK	1945762	D4200C0014	European, Observational, Prospective Study to Evaluate the Benefit/Risk of Vandetanib in RET Mutation Negative and Positive Patients With Symptomatic, Aggressive, Sporadic, Unresectable, Locally Advanced/Metastatic Medullary Thyroid Cancer	Observational Prospective	Symptomatic, Aggressive, Sporadic, Unresectable, Locally Advanced/Metastatic, Medullary Thyroid Cancer (MTC)	No Reclutando	Vandetanib 300mg	1 Site Barcelona H.U.12 Octubre	Genzyme, a Sanofi Company	Oncologia_Medica	N= 80